Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype

Journal of Immunology

Volumn 194, Issue 10, 2015, Pages 4997-5006

  Xu, Meng ^a,b   Liu, Mingyue ^a,b   Du, Xuexiang ^a,b   Li, Sirui ^a,b   Li, Hang ^a   Li, Xiaozhu ^a   Li, Ying ^a   Wang, Yang ^c   Qin, Zhihai ^a   Fu, Yang Xin ^a,c   Wang, Shengdian ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLODRONIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; INTERLEUKIN 21; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; INTRATUMORAL DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; DRUG RESISTANCE; EXPERIMENTAL MAMMARY NEOPLASM; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MACROPHAGE; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; TUMOR MICROENVIRONMENT;

EID: 84929103800     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402603     Document Type: Article

References (53)

1. Romond, E. H., E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, Jr., N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353: 1673-1684.
2. Hudis, C. A. 2007. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357: 39-51.
3. Piccart-Gebhart, M. J., M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al Herceptin Adjuvant (HERA) Trial Study Team. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353: 1659-1672.
4. Vogel, C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, et al. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20: 719-726.
5. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639-2648.
6. Seidman, A. D., M. N. Fornier, F. J. Esteva, L. Tan, S. Kaptain, A. Bach, K. S. Panageas, C. Arroyo, V. Valero, V. Currie, et al. 2001. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19: 2587-2595.
7. Nagata, Y., K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, K. S. Klos, P. Li, B. P. Monia, N. T. Nguyen, et al. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
8. Saez, R., M. A. Molina, E. E. Ramsey, F. Rojo, E. J. Keenan, J. Albanell, A. Lluch, J. Garcia-Conde, J. Baselga, and G. M. Clinton. 2006. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. 12: 424-431.
9. Scaltriti, M., F. Rojo, A. Ocaña, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, and J. Baselga. 2007. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 99: 628-638.
10. Nahta, R., L. X. Yuan, B. Zhang, R. Kobayashi, and F. J. Esteva. 2005. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65: 11118-11128.
11. Zhuang, G., D. M. Brantley-Sieders, D. Vaught, J. Yu, L. Xie, S. Wells, D. Jackson, R. Muraoka-Cook, C. Arteaga, and J. Chen. 2010. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70: 299-308.
12. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
13. Park, S., Z. Jiang, E. D. Mortenson, L. Deng, O. Radkevich-Brown, X. Yang, H. Sattar, Y. Wang, N. K. Brown, M. Greene, et al. 2010. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18: 160-170.
14. Mortenson, E. D., S. Park, Z. Jiang, S. Wang, and Y. X. Fu. 2013. Effective antineu-initiated antitumor responses require the complex role of CD4+ T cells. Clin. Cancer Res. 19: 1476-1486.
15. Stagg, J., S. Loi, U. Divisekera, S. F. Ngiow, H. Duret, H. Yagita, M. W. Teng, and M. J. Smyth. 2011. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 108: 7142-7147.
16. Denkert, C., S. Loibl, A. Noske, M. Roller, B. M. Müller, M. Komor, J. Budczies, S. Darb-Esfahani, R. Kronenwett, C. Hanusch, et al. 2010. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28: 105-113.
17. Denkert, C., S. Loibl, A. Noske, M. Roller, B. M. Müller, M. Komor, J. Budczies, S. Darb-Esfahani, R. Kronenwett, C. Hanusch, et al. 2010. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28: 105-113.
18. Farmer, P., H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, V. Becette, S. André, M. Piccart, M. Campone, E. Brain, et al. 2009. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15: 68-74.
19. Qian, B. Z., and J. W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
20. Coffelt, S. B., A. O. Tal, A. Scholz, M. De Palma, S. Patel, C. Urbich, S. K. Biswas, C. Murdoch, K. H. Plate, Y. Reiss, and C. E. Lewis. 2010. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 70: 5270-5280.
21. DeNardo, D. G., D. J. Brennan, E. Rexhepaj, B. Ruffell, S. L. Shiao, S. F. Madden, W. M. Gallagher, N. Wadhwani, S. D. Keil, S. A. Junaid, et al. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1: 54-67.
22. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11: 889-896.
23. Hagemann, T., T. Lawrence, I. McNeish, K. A. Charles, H. Kulbe, R. G. Thompson, S. C. Robinson, and F. R. Balkwill. 2008. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205: 1261-1268.
24. Stein, M., S. Keshav, N. Harris, and S. Gordon. 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176: 287-292.
25. Sica, A., T. Schioppa, A. Mantovani, and P. Allavena. 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42: 717-727.
26. Rolny, C., M. Mazzone, S. Tugues, D. Laoui, I. Johansson, C. Coulon, M. L. Squadrito, I. Segura, X. Li, E. Knevels, et al. 2011. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
27. Guiducci, C., A. P. Vicari, S. Sangaletti, G. Trinchieri, and M. P. Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65: 3437-3446.
28. Rovero, S., A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P. L. Lollini, et al. 2000. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165: 5133-5142.
29. Wei, W. Z., J. B. Jacob, J. F. Zielinski, J. C. Flynn, K. D. Shim, G. Alsharabi, A. A. Giraldo, and Y. C. Kong. 2005. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res. 65: 8471-8478.
30. Zhang, H., Q. Wang, K. T. Montone, J. E. Peavey, J. A. Drebin, M. I. Greene, and R. Murali. 1999. Shared antigenic epitopes and pathobiological functions of antip185(her2/neu) monoclonal antibodies. Exp. Mol. Pathol. 67: 15-25.
31. Van Rooijen, N., and A. Sanders. 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174: 83-93.
32. Ugai, S., O. Shimozato, K. Kawamura, Y. Q. Wang, T. Yamaguchi, H. Saisho, S. Sakiyama, and M. Tagawa. 2003. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 10: 187-192.
33. Ugai, S., O. Shimozato, L. Yu, Y. Q. Wang, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, S. Sakiyama, and M. Tagawa. 2003. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther. 10: 771-778.
34. Wang, G., M. Tschoi, R. Spolski, Y. Lou, K. Ozaki, C. Feng, G. Kim, W. J. Leonard, and P. Hwu. 2003. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63: 9016-9022.
35. Willimsky, G., M. Czéh, C. Loddenkemper, J. Gellermann, K. Schmidt, P. Wust, H. Stein, and T. Blankenstein. 2008. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 205: 1687-1700.
36. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
37. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
38. De Palma, M., and C. E. Lewis. 2011. Cancer: Macrophages limit chemotherapy. Nature 472: 303-304.
39. Kerkar, S. P., R. S. Goldszmid, P. Muranski, D. Chinnasamy, Z. Yu, R. N. Reger, A. J. Leonardi, R. A. Morgan, E. Wang, F. M. Marincola, et al. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121: 4746-4757.
40. Beatty, G. L., E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
41. Elsaesser, H., K. Sauer, and D. G. Brooks. 2009. IL-21 is required to control chronic viral infection. Science 324: 1569-1572.
42. Johnson, L. D., and S. C. Jameson. 2009. Immunology. A chronic need for IL-21. Science 324: 1525-1526.
43. Wan, C. K., J. Oh, P. Li, E. E. West, E. A. Wong, A. B. Andraski, R. Spolski, Z. X. Yu, J. He, B. L. Kelsall, and W. J. Leonard. 2013. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 38: 514-527.
44. Brandt, K., S. Bulfone-Paus, D. C. Foster, and R. Rückert. 2003. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102: 4090-4098.
45. Spolski, R., and W. J. Leonard. 2008. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26: 57-79.
46. Pelletier, M., A. Bouchard, and D. Girard. 2004. In vivo and in vitro roles of IL-21 in inflammation. J. Immunol. 173: 7521-7530.
47. Vallières, F., and D. Girard. 2013. IL-21 enhances phagocytosis in mononuclear phagocyte cells: identification of spleen tyrosine kinase as a novel molecular target of IL-21. J. Immunol. 190: 2904-2912.
48. Rückert, R., S. Bulfone-Paus, and K. Brandt. 2008. Interleukin-21 stimulates antigen uptake, protease activity, survival and induction of CD4+ T cell proliferation by murine macrophages. Clin. Exp. Immunol. 151: 487-495.
49. Pesce, J., M. Kaviratne, T. R. Ramalingam, R. W. Thompson, J. F. Urban, Jr., A. W. Cheever, D. A. Young, M. Collins, M. J. Grusby, and T. A. Wynn. 2006. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116: 2044-2055.
50. Thompson, J. A., B. D. Curti, B. G. Redman, S. Bhatia, J. S. Weber, S. S. Agarwala, E. L. Sievers, S. D. Hughes, T. A. DeVries, and D. F. Hausman. 2008. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 26: 2034-2039.
51. Davis, I. D., B. Brady, R. F. Kefford, M. Millward, J. Cebon, B. K. Skrumsager, U. Mouritzen, L. T. Hansen, K. Skak, D. Lundsgaard, et al. 2009. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin. Cancer Res. 15: 2123-2129.
52. Davis, I. D., B. K. Skrumsager, J. Cebon, T. Nicholaou, J. W. Barlow, N. P. Moller, K. Skak, D. Lundsgaard, K. S. Frederiksen, P. Thygesen, and G. A. McArthur. 2007. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13: 3630-3636.
53. Petrella, T. M., R. Tozer, K. Belanger, K. J. Savage, R. Wong, M. Smylie, S. Kamel-Reid, V. Tron, B. E. Chen, N. N. Hunder, et al. 2012. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J. Clin. Oncol. 30: 3396-3401.